|

NEXTGEN-TIL Clinical Trials

1 actively recruiting trial

Also known as: Tumor-infiltrating Lymphocyte Adoptive Cell Therapy

Pipeline

Early 1: 1

Top Sponsors

  • Vall d'Hebron Institute of Oncology1

Indications

  • Malignant Solid Tumor1
  • Epithelial Tumors, Malignant1
  • Cancer1

Other1 trial

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.